Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Tirzepatide Reports in EudraVigilance
A 2026 analysis of tirzepatide reports in EudraVigilance found reporting patterns, not individual risks or proof of causation.
How Tirzepatide May Raise Heart Rate
A human stem-cell study links tirzepatide to faster pacemaker-cell beating through cAMP and calcium signalling, but it is not a patient trial.
Tirzepatide and Male Fertility
A 2026 review finds a plausible research question around tirzepatide and male reproductive health, but direct human fertility evidence remains limited.
What a 2026 obesity-drug review found
A 2026 scoping review found the largest weight-loss results with incretin-based obesity medicines, while long-term questions remain.
Dual GLP-1/glucagon agonists: review
A 2026 review finds dual GLP-1/glucagon agonists reduce weight in trials, while separating them from retatrutide's three-receptor profile.
GLP-1 skin reactions: what two cases show
Two case reports link GLP-1 medicines to unusual skin reactions. Here is what they observed, and why they cannot establish risk or causation.
Low-Dose Tirzepatide in Japanese Care
A Japanese real-world study found lower HbA1c and BMI after 24 weeks of low-dose tirzepatide, with important design limits.
Oral semaglutide and water intake
A new oral semaglutide paper examines water measurement during simulated administration. Here is what the record and current label support.
Retatrutide Phase 3 Obesity Results
A Phase 3 trial reports retatrutide reduced mean body weight by 25.0% at 80 weeks in its highest-dose group versus placebo.
Semaglutide, CKD and Australia
An Australian panel places semaglutide's FLOW kidney results within shared care for type 2 diabetes and chronic kidney disease.
Tirzepatide heart risk after 1 year
A Mayo Clinic observational study links one year of tirzepatide use with improved risk markers, not proven prevention of cardiovascular events.
Tirzepatide and muscle loss: what we know
Tirzepatide weight loss includes fat and lean mass changes. Here is what body composition research can, and cannot, tell you.